MAPT and Alzheimer disease: While existing pharmacotherapies provide symptomatic relief, therapeutic standardization remains hindered by considerable clinical and neuropathological heterogeneity in AD, including divergent Aβ/tau deposition profiles and non-canonical phenotypic presentations (4).